Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

meda pharma gmbh & co. kg (8043598) - estradiol-hemihydrat - filmtablette - teil 1 - filmtablette; estradiol-hemihydrat (27668) 1,033 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

meda pharma gmbh & co. kg (8043598) - estradiol-hemihydrat - filmtablette - teil 1 - filmtablette; estradiol-hemihydrat (27668) 2,066 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

medis ehf (8020433) - granisetronhydrochlorid - filmtablette - teil 1 - filmtablette; granisetronhydrochlorid (24571) 1,12 milligramm

Europäische Union - Deutsch - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastische mittel - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Europäische Union - Deutsch - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

fujisawa deutschland gmbh - equilin-3-hydrogensulfat-natriumsalz, natrium(estron-3-sulfat) - dragees - equilin-3-hydrogensulfat-natriumsalz 0.2mg; natrium(estron-3-sulfat) 0.8mg

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ibrutinibum - kapseln - ibrutinibum 140 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172, propylenglycolum, pro capsula corresp. natrium 2.73 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 140 mg, lactosum monohydricum 28 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp. natrium 1.14 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 280 mg, lactosum monohydricum 56 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp., natrium 2.28 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 420 mg, lactosum monohydricum 84 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp. natrium 3.42 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika